Abstract
Introduction
Bone pain is a common symptom of metastatic disease in cancer, experienced with various intensities by about 30% of cancer patients, during the development of their disease, up to 60–90% in the latest phases.
Discussion
In addition to other therapies, such as analgesics, bisphosphonates, chemotherapy, hormonal therapy and external beam radiotherapy, bone-seeking radiopharmaceuticals are also used for the palliation of pain from bone metastases. Substantial advantages of bone palliation radionuclide therapy include the ability to simultaneously treat multiple sites of disease with a more probable therapeutic effect in earlier phases of metastatic disease, the ease of administration, the repeatability and the potential integration with the other treatments.
Conclusion
The Therapy, Oncology and Dosimetry Committees have worked together to revise the EANM guidelines on the use of bone-seeking radiopharmaceuticals. The purpose of this guideline is to assist the nuclear medicine physician in treating and managing patients undergoing such treatment.
Similar content being viewed by others
References
Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997;69:1–19.
Krishnamurthy GT, Krishnamurthy S. Radionuclides for metastatic bone pain palliation: a need for rational re-evaluation in the new millennium. J Nucl Med 2000;41(4):688–91.
Edwards GK, Santoro J, Taylor AT, et al. Use of bone scintigraphy to select patients with multiple myeloma for treatment with strontium-89. J Nucl Med 1994;35:1992–4.
Lewington VJ. Bone-seeking radiopharmaceuticals. J Nucl Med 2005;46:38S–47S.
Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol 2005;6(6):392–400. June 6.
Taylor AJ Jr. Strontium-89 for the palliation of bone pain due to metastatic disease. J Nucl Med 1994;35:2054.
Farhanghi M, Holmes RA, Volkert WA, et al. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med 1992;33:1451–8.
De Klerk JMH, Zonnenberg BA, Blijham GH, et al. Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP. Anticancer Res 1997;17:1773–8.
IAEA. Criteria for palliation of bone metastases—clinical applications. IAEA-TECDOC-1549. IAEA, Vienna, 2007. Retrieved from http://www-pub.iaea.org/MTCD/publications/PDF/te_1549_web.pdf.
Collins C, Eary JF, Donaldson G, et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med 1993;34:1839–44.
Robinson RG, Blake GM, Preston DF, et al. Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics 1989;9:271–81.
Turner SL, Gruenewald S, Spry N, on behalf of the Metastron Users Group, et al. Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer. Br J Cancer 2001;84(3):297–302.
James ND, Bloomfield D, Luscombe C. The changing pattern of management for hormone-refractory, metastatic prostate cancer. Prostate Cancer Prostatic Dis 2006;9:221–9.
McEwan AJ, Amyotte GA, McGowan DG, et al. A retrospective analysis of the cost effectiveness of treatment with Metastron (Sr-89-Cl) in patients with prostate cancer metastatic to bone. Nucl Med Common 1994;15:499–504.
McEwan AJ, Porter AT, Venner PM, et al. An evaluation of the safety and efficacy of treatment with strontium-89 in patients who have previously received wide field radiotherapy. Antibod Immunoconj Radiopharm 1990;3:91–8.
Porter AT, McEwan AJ, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993;25:805–13.
Quilty PM, Kirk D, Bolger JJ, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994;31:33–40.
Paszkowski AL, Hewitt DJ, Taylor A Jr. Disseminated intravascular coagulation in a patient treated with strontium-89 for metastatic carcinoma of the prostate. Clin Nucl Med 1999;24(11):852–4.
Hamdy NA, Papapoulos SE. The palliative management of skeletal metastases in prostate cancer: use of bone-seeking radionuclides and bisphosphonates. Semin Nucl Med 2001;31(1):62–8, January.
Lam MG, Dahmane A, Stevens WH, van Rijk PP, de Klerk JM, Zonnenberg BA. Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases. Eur J Nucl Med Mol Imaging 2007;35(4):756–64.
Lamb HM, Faulds D. Samarium-153-lexidronam. Drugs Aging 1997;11:413–8. discussion 419.
Fuster D, Herranz R, Alcover J, Mateos JJ, Martín F, Vidal-Sicart S, Pons F. Treatment of metastatic bone pain with repeated doses of strontium-89 in patients with prostate neoplasm. Rev Esp Med Nucl 2000;19(4):270–4, August.
Sartor O, Reid RH, Bushnell DL, et al. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer 2007;109(3):637–43.
Oosterhof GO, Roberts JT, de Reijke TM, Engelholm SA, Horenblas S, von der Maase H, Neymark N, Debois M, Collette L. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol 2003;44(5):519–26. November.
Papatheofanis FJ. Variation in oncologic opinion regarding management of metastatic bone pain with systemic radionuclide therapy. J Nucl Med 1999;40(9):1420–3, September.
Tu SM, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S, General R, Podoloff DA, Lin SH, Logothetis CJ. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol 20051;23(31):7904–10. November.
Sciuto R, Festa A, Rea S, Pasqualoni R, Bergomi S, Petrilli G, Maini CL. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 2002;43:79–86.
Windsor PM. Predictors of response to strontium-89 (Metastron) in skeletal metastases from prostate cancer: report of a single centre’s 10-year experience. Clin Oncol (R Coll Radiol) 2001;13(3):219–27.
Zyskowski A, Lamb D, Morum P, Hamilton D, Johnson C. Strontium-89 treatment for prostate cancer bone metastases: does a prostate-specific antigen response predict for improved survival? Australas Radiol 2001;45:39–42.
Pagliaro LC, Delpassand ES, Williams D, Millikan RE, Tu SM, Logothetis CJ. A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases. Cancer 2003;97(12):2988–94. June 15.
Silberstein EB. Teletherapy and radiopharmaceutical therapy of painful bone metastases. Semin Nucl Med 2005;35(2):152–8, April.
Administration of Radioactive Substances Advisory Committee. Notes for Guidance on the Clinical Administration of Radiopharmaceuticals and Use of Sealed Radioactive Source. 2000. Retrieved from http://www.arsac.org.uk/notes_for_guidence/docs/arsac_nfg.pdf.
Silberstein EB, Williams C. Strontium-89 therapy for the pain of osseous metastases. J Nucl Med 1985;26:345–8.
Resche I, Chatal JF, Pecking A, et al. A dose-controlled study of 153Sm EDTMP in the treatment of patients with painful bone metastases. Eur J Cancer 1997;33:1583–91.
ICRP Publication 53: Radiation Dose to Patients from Radiopharmaceuticals, 53 Annals of the ICRP Volume 18/1–4.
Eary JF, Collins C, Stabin M, Vernon C, Petersdorf S, Baker M, et al. Samarium-153-EDTMP Biodistribution and Dosimetry Estimation. J Nucl Med 1993;34:1031–6.
Graham MC, Scher HI, Liu GB, Yeh SD, Curley T, Daghighian F, et al. Rhenium-186-labeled hydroxyethylidene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen-independent prostate cancer. Clin Cancer Res 1999;5(6):1307–18.
Herold TJ, Gross GP, Hung JC. A technique for measurement of strontium-89 in a dose calibrator. J Nucl Med Technol 1995;23:26–8.
Conflict of interest statement
None of the authors have any conflict or duality of interests.
Last amended
March 2008.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bodei, L., Lam, M., Chiesa, C. et al. EANM procedure guideline for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging 35, 1934–1940 (2008). https://doi.org/10.1007/s00259-008-0841-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-008-0841-y